]>
IRCT20200823048493N1 IRCT 2020-10-25 Ahvaz University of Medical Sciences The effect of magnesium supplementation in improving depressive symptoms in patients with major depressive disorder treated with antidepressants The effect of adding magnesium supplement on depressive symptoms in patients with major depressive disorder treated with antidepressants (SSRI 2019-06-10 anticipated 48 Complete https://irct.ir/trial/51743 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: We divided each referral into two groups using a randomized table. This table was a collection of numbers. We Considered number from 1 to 24 for intervention and numbers 25 to 48 for control. Then we toughed one of the numbers and moved in one of the preset directions and assigned the numbers to one of the groups. Thus, patients were completely randomly divided, Blinding description: In this study, patients did not know about prescription drugs (placebo and drug). Also, the researcher (the person who provided these drugs to the patients) did not know about the assignment of patients to placebo and drug. 3 Major Depressive Disorder. Intervention 1: The intervention group was treated with selective serotonin inhibitors (sertraline, citalopram, fluoxetine and fluoxacin) along with magnesium supplement at a dose of 250 mg per day for 6 weeks. Intervention 2: The intervention group was treated with selective serotonin inhibitors (sertraline, citalopram,fluoxetine and fluoxacin) along with placebo per day for 6 weeks. No - There is not a plan to make this available Justification or reason for not sharing IPD is Participants' consent for publication must be available
public Susan Sadeghi
Ahwas University of Medical Sciences, Golestan Blvd, Ahwaz
Ahwaz Iran (Islamic Republic of) 15794 -61357 +98 61 3374 3001 dr.sadeghi_45@yahoo.com Ahvaz University of Medical Sciences scientific Susan Sadeghi
Ahwaz University of Medical Sciences, Golestan Blvd, Ahwaz
Ahwaz Iran (Islamic Republic of) 15794 - -61357 +98 61 3374 3001 dr.sadegh_45@yahoo.com Ahvaz University of Medical Sciences Iran (Islamic Republic of) Patients with major depression based on DSM-S and according to the diagnosis of a psychiatrist Age over 18 years Having minimum education to read the questionnaire 18 years 70 years Both Neurological disorders Taking alcohol and drug use during the last 6 months Active suicidal thoughts Pregnancy and lactation Mental retardation Liver and kidney failure Receiving monooxidase inhibitors during the last 8 weeks History of seizures Taking magnesium-interfering drugs Presence of uncontrolled diseases such as diabetes and high blood pressure Allergy to antidepressants or magnesium supplements F32.3 Major depressive disorder, single episode, severe with psychotic features Treatment - Drugs Treatment - Drugs The intervention group was treated with selective serotonin inhibitors (sertraline, citalopram, fluoxetine and fluoxacin) along with magnesium supplement at a dose of 250 mg per day for 6 weeks. The intervention group was treated with selective serotonin inhibitors (sertraline, citalopram,fluoxetine and fluoxacin) along with placebo per day for 6 weeks. Depression. Timepoint: In weeks 0, 2, 4 6. Method of measurement: Via Beck Depression Inventory. Side effects such as diarrhea. Timepoint: 6 weeks after intervention. Method of measurement: Through questions from the patient. Ahvaz University of Medical Sciences Approved 2020-02-24 Ethics Committee of Ahwaz University of Medical Sciences Ahwaz University of Medical Sciences, Golestan Blvd, Ahwaz ŮŽAhwaz Khouzestan Iran (Islamic Republic of)